GlaxoSmithKline Finds High Efficacy Rate in Study of Two-Drug HIV Regimen
25 July 2019 - 2:02AM
Dow Jones News
By Adriano Marchese
GlaxoSmithKline PLC (GSK.LN) said Wednesday that a study found
high efficacy rates and no cases of treatment emergent resistance
for its two HIV drugs, Dolutegravir and Lamivudine.
ViiV Healthcare, of which GlaxoSmithKline is a majority
shareholder, said that week 96 data from the GEMINI studies
demonstrate that the clinical benefits of Dolutegravir plus
Lamivudine at week 48 are sustainable. It also said that the
findings provide further evidence of the benefits of two-drug
regimen.
"These latest findings are important for people living with HIV
who will potentially spend decades taking medication to manage
their HIV," Principal Investigator for the GEMINI study program,
Pedro Cahn, said.
Write to Adriano Marchese at adriano.marchese@dowjones.com
(END) Dow Jones Newswires
July 24, 2019 11:47 ET (15:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2024 to Jul 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Jul 2023 to Jul 2024